Results from the phase 3 Embark trial demonstrate that combining Xtandi with leuprolide significantly improves overall survival in patients with non-metastatic hormone-sensitive prostate cancer exhibiting biochemical recurrence. This establishes Xtandi as the first androgen receptor inhibitor regimen to extend lives in this group. The data reinforce the drug's expanded role earlier in prostate cancer treatment and highlight substantial growth in its global sales.